Search PubMed⌕ Search

Biomedical subjects

S B Gusberg

Publications and source records attributed to S B Gusberg.

At least 19 recordsLinked to original sources
PubMed1993

Virulence factors in endometrial cancer.

The majority of endometrial cancers are relatively benign and curable; there is a subset of virulent tumors that demands recognition. Factors that must be evaluated include: tumor grade, ploidy, steroid receptors, myometrial invasion, lymph node status, extrauterine disease or positive peritoneal fluid, and certain special tumors. These tumors of special virulence include: papillary adenocarcinoma, papillary serous adenocarcinoma, adenosquamous carcinoma, and clear cell carcinoma. Virulent tumors (approximately 20%) require special consideration and special treatment.

Adenocarcinoma↗
PubMed1988

Detection and prevention of uterine cancer.

The two major uterine cancers, squamous carcinoma of the cervix and adenocarcinoma of the endometrium, are highly vulnerable to detection technology and, therefore, secondary prevention. High risk groups for each have been defined, cancer precursors described, i.e., dysplasia of the cervix and adenomatous hyperplasia of the endometrium, and efficient screening methods made available. For the cervical tumor cytologic testing is most appropriate, while histologic screening is more efficient for endometrial precursor lesions. The strategies of approach of these accessible tumors are models for detection and prevention methods elsewhere in the body and we should exploit them to virtual eradication of these uterine tumors.

Carcinoma↗
PubMed1987

An era of therapeutic translation.

Diagnostic advances currently have exceeded therapeutic gain. The present, however, is a transition phase. Chemotherapy, for example, has become curative for some tumors in recent years, rather than merely palliative, due to the precision permitted by advances in molecular biology. At this time, acceleration in the basic oncologic sciences has surpassed therapeutic advance, but therapeutic translation has begun and we will require clinical scientists to increase the bridge from laboratory to bedside if we are to speed the contribution of the so-called biologic revolution to cancer control.

Female↗
PubMed1986

Endometrial cancer. Epidemiology.

In evaluating these trends in the East-West comparison, one notes that the epidemiologic features connoting high risk are similar in both cultures; while they are more common in the West, they are more strongly associated in the East. Clearly, a prospective interview method of obtaining reproductive data will be more informative for such a crosscultural study with greater numbers lending better support. In summary, there exists a grouping of reproductive phenomena fairly common in Western societies that are related to higher risk for endometrial cancer, and we have noted similar characteristics in Eastern women who have developed this disease, while control groups in Eastern societies where this disease is uncommon have a low profile for such attributes in comparison to the West.

Age Factors↗
PubMed1984

Ovarian dysplasia. A study of identical twins.

The normal, identical twin sisters of patients who had been the subjects of ovarian cancer were subjected to prophylactic oophorectomy after the menopause. The finding of epithelial abnormality suggests a precancerous change similar to other genital epithelial dysplasia.

Aged↗
PubMed1983

The diagnosis of gynecologic cancer.

Malignant tumors of the female reproductive tract may be divided into the accessible and the inaccessible. Cancer of the vulva, cervix, and endometrium fall into the accessible group and they are characterized by knowledge of their precursor lesions and efficient screening or detection methods. Although we have not achieved total surveillance of our adult female population, we can expect to achieve prevention or early diagnosis of these tumors as we educate the public to the possibility of prevention and control. In the case of the inaccessible tumors, such as in ovarian cancer, we are still dependent upon physical examination and its adjuvants, for symptoms are late and no screening measure has been found effective to this date. Research into possible tumor markers, biochemical or immunological, are being investigated for the earlier diagnosis of this disease. Abnormal uterine bleeding requires tissue diagnosis before institution of any treatment. The primary physician's office is the most important site for cancer screening and it is the physician's responsibility to stay abreast of new information available in the oncologic disciplines, since cancer is the second most common cause of death in our country.

Female↗
PubMed1983

Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO Stages III and IV) as measured by surgical end-staging (second-look operation).

Between 1974 and 1982, 273 patients with epithelial cancer of the ovary (International Federation of Gynaecology and Obstetrics Stages III and IV) were randomized in four therapeutic trials. In Trial I Adriamycin plus cisplatin versus cisplatin alone versus thiotepa plus methotrexate was tested. The superiority of Adriamycin plus cisplatin in producing the best response rate led to its use as the reference arm in subsequent trials. All investigational arms included cisplatin plus other drugs (cyclophosphamide, Adriamycin, hexamethylmelamine, and thiotepa) in various combinations. Eligibility for second look required complete clinical remission and completion of at least 10 cycles of chemotherapy. To date, 73 second-look operations have been performed on randomized patients. An additional 43 nonrandomized patients underwent second-look procedures and are analyzed separately. Between 40% and 46% of patients treated with cisplatin regimens had no disease at second look. Cell differentiation and volume of postoperative disease did not influence response.

Aged↗
PubMed1983

Cisplatin regimens and improved prognosis of patients with poorly differentiated ovarian cancer.

Patients with advanced ovarian carcinoma, Stage III or IV (International Federation of Gynaecology and Obstetrics), were randomized to primary chemotherapy with doxorubicin (Adriamycin) and cisplatin plus or minus hexamethylmelamine, and cyclophosphamide (CHAP). The four-drug CHAP regimen produced a 57% complete clinical response rate and a 26% partial response rate for clinically evaluable patients. The median survival of CHAP patients is 25 months. The two-drug Adriamycin-cisplatin (AP) regimen produced a 43% complete response rate and a 35% partial response rate. The median survival is 18 months. The four-drug regimen produced a significantly longer median survival (28 versus 18 months) for patients with poorly differentiated tumors than for patients with well-differentiated tumors on either treatment. Examination of treatment failure or death by treatment, histology, and size of largest residual tumor and comparison to similar patients treated with AP in this and two preceding controlled trials also suggest that CHAP is superior to AP for patients with poorly differentiated tumors.

Altretamine↗